Deig C, Trone K, Beneville B, Stratton A, Liu A, Kanwar A, Grossblatt-Wait A, Sheppard B, Attia F, Bassale S, Chen Y, Keith D, Chen E, Lopez C, Gilbert E, Billingsley K, Nabavizadeh N, Thomas C, Grossberg A. Borderline Resectable Pancreatic Cancer Patients Have Superior Survival Following Neoadjuvant Therapy Compared to Upfront Resectable Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e581-e582. DOI: 10.1016/j.ijrobp.2020.07.1786.Peer-Reviewed Original Research